professionalIMG

Pamela B. Greene

Member
617.348.1623
vCard
Boston


Education

  • Boston University (JD, 1991)
  • McGill University (BCOMM, Finance / International Business, 1986)

Bar Admissions

  • Massachusetts

Pam counsels the firm’s public company clients with respect to securities compliance under both the Securities Act of 1933 and the Securities Exchange Act of 1934; executive compensation-related issues; and corporate governance matters, including compliance with stock exchange requirements, the Sarbanes-Oxley Act of 2002, and the Dodd-Frank Act of 2010. She also advises and represents public and private companies and individuals on all aspects of equity compensation matters.

Pam works with clients’ management teams, boards, and compensation committees to develop and design appropriate executive compensation programs, and to resolve legal issues confronting employers when implementing and revising such programs. She provides executive compensation and securities counsel to clients in merger and acquisition transactions

Before joining Mintz Levin, Pam was an associate in the business practice group of another premier Boston-based law firm. She has advised venture capital fund clients and participated in the organization of venture capital funds. Pam has also handled corporate and securities law matters for a range of businesses, including entrepreneurial companies and private equity investors. She represented both corporations and investors in private placements, public offerings, mergers and acquisitions, and general corporate law matters.

Before attending law school, Pam worked as a corporate service representative for the Boston Trade Bank from its inception as a start-up venture. In that capacity, she handled cash management products and worked with clients to maximize short-term corporate funds.

Representative Matters

  • Lantos Technologies, Inc. in its Series C financing
  • Intercept Pharmaceuticals, Inc. in the filing of its initial public offering
  • ADVANDX Pharmaceuticals, Inc. in its Series D financing
  • Ember Corporation in its sale to Silicon Laboratories, Inc.
  • Vringo, Inc. in its merger with Innovate/Protect, Inc.
  • Caliper Life Sciences, Inc. in its sale to PerkinElmer, Inc.
  • Microfluidics International Corporation in its sale to IDEX Corporation
  • Arbinet Corporation in its sale to Primus Telecommunications Group, Inc.
  • Biocius Life Sciences, Inc. in its sale to Agilent Technologies
  • AMICAS, Inc. in its sale to Merge Healthcare
  • Myriad Genetics, Inc. in its spin-off transaction, which resulted in a new public company, Myriad Pharmaceuticals, Inc.
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its acquisition of ViroChem Pharma, Inc.
  • QIAGEN NV in its acquisition of Digene, Inc.

Recognitions & Awards

  • Paul J. Liacos Distinguished Scholar
  • Edward F. Hennessey Scholar
  • G. Joseph Tauro Scholar

Professional & Community Involvement

  • Member, National Association of Stock Plan Professionals